165 related articles for article (PubMed ID: 34924387)
1. Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.
Teipel SJ; Dyrba M; Ballarini T; Brosseron F; Bruno D; Buerger K; Cosma NC; Dechent P; Dobisch L; Düzel E; Ewers M; Fliessbach K; Haynes JD; Janowitz D; Kilimann I; Laske C; Maier F; Metzger CD; Munk MH; Peters O; Pomara N; Preis L; Priller J; Ramírez A; Roy N; Scheffler K; Schneider A; Schott BH; Spottke A; Spruth EJ; Wagner M; Wiltfang J; Jessen F; Heneka MT
J Alzheimers Dis; 2022; 85(3):1267-1282. PubMed ID: 34924387
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Basal Forebrain Degeneration Interacts with TREM2/C3 Biomarkers of Inflammation in Presymptomatic Alzheimer's Disease.
Schmitz TW; Soreq H; Poirier J; Spreng RN
J Neurosci; 2020 Feb; 40(9):1931-1942. PubMed ID: 31915256
[TBL] [Abstract][Full Text] [Related]
3. Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder.
Teipel S; Bruno D; Plaska CR; Heslegrave A; Ramos-Cejudo J; Osorio RS; Zetterberg H; Blennow K; Pomara N
J Affect Disord; 2021 Oct; 293():429-434. PubMed ID: 34246952
[TBL] [Abstract][Full Text] [Related]
4. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
5. Glial activation and inflammation along the Alzheimer's disease continuum.
Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
[TBL] [Abstract][Full Text] [Related]
6. Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer's disease spectrum.
Herdick M; Dyrba M; Fritz HJ; Altenstein S; Ballarini T; Brosseron F; Buerger K; Can Cetindag A; Dechent P; Dobisch L; Duezel E; Ertl-Wagner B; Fliessbach K; Dawn Freiesleben S; Frommann I; Glanz W; Dylan Haynes J; Heneka MT; Janowitz D; Kilimann I; Laske C; Metzger CD; Munk MH; Peters O; Priller J; Roy N; Scheffler K; Schneider A; Spottke A; Jakob Spruth E; Tscheuschler M; Vukovich R; Wiltfang J; Jessen F; Teipel S; Grothe MJ
Neuroimage Clin; 2020; 28():102495. PubMed ID: 33395986
[TBL] [Abstract][Full Text] [Related]
7. MRI-based basal forebrain atrophy and volumetric signatures associated with limbic TDP-43 compared to Alzheimer's disease pathology.
Teipel S; Grothe MJ;
Neurobiol Dis; 2023 May; 180():106070. PubMed ID: 36898615
[TBL] [Abstract][Full Text] [Related]
8. Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration.
Fernández-Cabello S; Kronbichler M; Van Dijk KRA; Goodman JA; Spreng RN; Schmitz TW;
Brain; 2020 Mar; 143(3):993-1009. PubMed ID: 32203580
[TBL] [Abstract][Full Text] [Related]
9. Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study.
Brueggen K; Dyrba M; Barkhof F; Hausner L; Filippi M; Nestor PJ; Hauenstein K; Klöppel S; Grothe MJ; Kasper E; Teipel SJ
J Alzheimers Dis; 2015; 48(1):197-204. PubMed ID: 26401940
[TBL] [Abstract][Full Text] [Related]
10. Antemortem basal forebrain atrophy in pure limbic TAR DNA-binding protein 43 pathology compared with pure Alzheimer pathology.
Teipel SJ; Grothe MJ;
Eur J Neurol; 2022 May; 29(5):1394-1401. PubMed ID: 35122358
[TBL] [Abstract][Full Text] [Related]
11. Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson's disease.
Schumacher J; Kanel P; Dyrba M; Storch A; Bohnen NI; Teipel S; Grothe MJ
Brain; 2023 Dec; 146(12):4964-4973. PubMed ID: 37403733
[TBL] [Abstract][Full Text] [Related]
12. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
13. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.
Rauchmann BS; Schneider-Axmann T; Alexopoulos P; Perneczky R;
Neurobiol Aging; 2019 Feb; 74():182-190. PubMed ID: 30458365
[TBL] [Abstract][Full Text] [Related]
14. Independent and additive contribution of white matter hyperintensities and Alzheimer's disease pathology to basal forebrain cholinergic system degeneration.
Kindler C; Upadhyay N; Bendella Z; Dorn F; Keil VC; Petzold GC
Neuroimage Clin; 2023; 39():103477. PubMed ID: 37478584
[TBL] [Abstract][Full Text] [Related]
15. Basal forebrain septal nuclei are enlarged in healthy subjects prior to the development of Alzheimer's disease.
Butler T; Harvey P; Deshpande A; Tanzi E; Li Y; Tsui W; Silver C; Fischer E; Wang X; Chen J; Rusinek H; Pirraglia E; Osorio RS; Glodzik L; de Leon MJ
Neurobiol Aging; 2018 May; 65():201-205. PubMed ID: 29499501
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease.
Gispert JD; Suárez-Calvet M; Monté GC; Tucholka A; Falcon C; Rojas S; Rami L; Sánchez-Valle R; Lladó A; Kleinberger G; Haass C; Molinuevo JL
Alzheimers Dement; 2016 Dec; 12(12):1259-1272. PubMed ID: 27423963
[TBL] [Abstract][Full Text] [Related]
17. Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome.
Rozalem Aranha M; Iulita MF; Montal V; Pegueroles J; Bejanin A; Vaqué-Alcázar L; Grothe MJ; Carmona-Iragui M; Videla L; Benejam B; Arranz J; Padilla C; Valldeneu S; Barroeta I; Altuna M; Fernández S; Ribas L; Valle-Tamayo N; Alcolea D; González-Ortiz S; Bargalló N; Zetterberg H; Blennow K; Blesa R; Wisniewski T; Busciglio J; Cuello AC; Lleó A; Fortea J
Alzheimers Dement; 2023 Nov; 19(11):4817-4827. PubMed ID: 37021589
[TBL] [Abstract][Full Text] [Related]
18. Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD).
Scheef L; Grothe MJ; Koppara A; Daamen M; Boecker H; Biersack H; Schild HH; Wagner M; Teipel S; Jessen F
Neuroimage Clin; 2019; 21():101612. PubMed ID: 30555006
[TBL] [Abstract][Full Text] [Related]
19. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
20. Association Between Smoking and Cholinergic Basal Forebrain Volume in Healthy Aging and Prodromal and Dementia Stages of Alzheimer's Disease.
Teipel S; Grothe MJ;
J Alzheimers Dis; 2016 Apr; 52(4):1443-51. PubMed ID: 27079707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
